

10/02/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KREIDER *et al.*

Appl. No. 10/054,967

Filed: January 25, 2002

For: **Methods of Using Chemokine β-6**

Confirmation No. 9197

Art Unit: 1646

Examiner: *To be assigned*

Atty. Docket: 1488.034000B/EKS/HCC/VSR

**First Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on July 18, 2002, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473

Date: \_\_\_\_\_

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600  
SKG:Rev. 124 02 mac

Sept 16, 2002  
Enclosed



October 1, 2002

WRITER'S DIRECT NUMBER:

(202) 371-2641

INTERNET ADDRESS:

HELENECARLSON@SKED.COM

Commissioner for Patents  
Washington, D.C. 20231

*Group Art Unit 1646*

Re: U.S. Utility Patent Application  
Appl. No. 10/054,967; Filed: January 25, 2002  
For: **Methods of Using Chemokine B-6**  
Inventors: Kreider *et al.*  
Our Ref: 1488.034000B/EKS/HCC/VSR

10/02/02

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. A listing of the cited documents on Form PTO-1449;
3. Copies of the cited documents on Form PTO-1449 (AO2, AT20, and AR21); and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KLEISSER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473

EKS HCC VSR skm  
Enclosures  
skm (w/ 88-12)